Boston Gene to Display Its Multidimensional AI Platform Accelerating Pharmaceutical Advancements at the 2025 ASCO® Annual Conference
At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, BostonGene Corporation showcased groundbreaking innovations in precision oncology, emphasising the transformative power of AI-driven multiomic approaches in cancer treatment.
The event, held from May 31 to June 3 at McCormick Place Convention Center in Chicago, IL, saw Lev Bedniagin, MD from BostonGene presenting several studies. One of these focused on tertiary lymphoid structures and their association with immune checkpoint inhibitor response and survival outcomes in patients with non-small cell lung cancer. Another study delved into detecting hotspots of intra- and transchromosomal fusions in liposarcomas by RNA sequencing.
In addition, Nikita Kotlov from BostonGene presented a study on molecular subtyping and insights into sarcoma biology and prognosis. These studies leveraged BostonGene's AI-driven Kassandra deconvolution algorithm to analyse transcriptomic data from patients with non-small cell lung cancer and other tumour types.
The BostonGene Tumor Portrait test, a key tool in their arsenal, was used to characterise Cancer of Unknown Primary (CUP) in a study. The test demonstrated clinical utility in guiding treatment selection for castrate-resistant prostate cancer based on tumour microenvironment-related gene signatures.
Across six accepted studies, BostonGene demonstrated how its platform uncovers novel biomarkers, refines patient stratification, and predicts therapeutic response across various tumour types. For instance, the study on invasive lobular carcinoma, done in collaboration with MD Anderson, identified unique histologic and molecular findings.
The presentations at ASCO 2025 underscored the importance of precision medicine in managing cancer subtypes that are resistant to traditional interventions. Joelle Allam from The Texas University MD Anderson Cancer Center will present a study on uncovering the Tumor Microenvironment (TME) in Cancer of Unknown Primary (CUP).
BostonGene's AI platform, which combines deep molecular profiling, immune system characterisation, and advanced analytics, was recognised with the GRASP Advocate Choice Award at ASCO 2025. For more information, please visit the 2025 ASCO Annual Meeting website. BostonGene will exhibit at booth #15147.
In conclusion, BostonGene's presentations at ASCO 2025 conveyed a clear and confident message that AI-driven multiomic approaches are redefining cancer treatment by enhancing biomarker discovery, refining patient stratification, and optimising oncology trial designs. This positions BostonGene as a leading innovator in marrying precision medicine with artificial intelligence to transform oncology drug development.
- The AI-driven Kassandra deconvolution algorithm from BostonGene, demonstrated at the 2025 ASCO Annual Meeting, was employed in studies analyzing transcriptomic data from patients with non-small cell lung cancer and other tumor types, thereby contributing to the field of precision oncology.
- Held at McCormick Place Convention Center in Chicago, IL, the American Society of Clinical Oncology (ASCO) Annual Meeting showcased BostonGene's innovations in health-and-wellness and medical-conditions industries, highlighting their impact on health-and-wellness through transformative precision medicine.
- In addition to pioneering advancements in cancer treatment, BostonGene's AI platform was recognized with the GRASP Advocate Choice Award at ASCO 2025, reflecting its significance in the business and technology sectors, particularly in the finance and science industries.
- The BostonGene Tumor Portrait test, integral to their arsenal, was used to study Cancer of Unknown Primary (CUP) at ASCO 2025, demonstrating its potential to impact the financial industry by generating lucrative business opportunities through improved cancer diagnostics.
- The work presented by Joelle Allam from The Texas University MD Anderson Cancer Center and other researchers at ASCO 2025 emphasized the critical role of artificial intelligence in any scientific endeavor, such as precision medicine, serving as a testament to its growing importance in the science and technology industries.
